SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Half a decade of mini-pool nucleic acid testing: Cost-effective way for improving blood safety in India
9 references·5 citing·45 second hop
Half a decade of mini-pool nucleic acid testing: Cost-effective way for improving blood safety in India (2014)Half a decade of mini-pool nucleic acid t…Need for Nucleic Acid Testing in Countries with High Prevalence of Transfusion-Transmitted Infections (2012)Need for Nucleic Acid Testing…Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing (2010)Prevalence, incidence, and re…Patterns of infections among blood donors in a tertiary care centre: a retrospective study. (2010)Patterns of infections among …Nucleic acid testing (NAT) in high prevalence–low resource settings (2010)Nucleic acid testing (NAT) in…Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions (2009)Experience of mandatory nucle…Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus -1 & hepatitis B & C viruses in Indian blood donors. (2008)Multicenter evaluation of ind…The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donations (2003)The cost‐effectiveness of NAT…Yield of HCV and HIV‐1 NAT after screening of 3.6 million blood donations in central Europe (2002)Yield of HCV and HIV‐1 NAT af…Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window‐phase donations not detected by NAT (2002)Mathematic modeling of the ri…Blood Donation Screening of Transfusion-Transmissible Viral Infection Using Two Different Nucleic Acid Testing (NAT) Platforms: A Single Tertiary Care Oncology Centre Experience (2022)Blood Donation Screening of T…Seven Years Experience in NAT Testing of Blood Donors in a Tertiary Care Centre (2019)Seven Years Experience in NAT…A study of centralized individual donor nucleic acid testing for transfusion transmitted infections to improve blood safety in Karnataka, India (2017)A study of centralized indivi…Nucleic A cid T echnology ( NAT ) testing for blood screening: impact of individual donation and M ini P ool – NAT testing on analytical sensitivity, screening sensitivity and clinical sensitivity (2014)Nucleic A cid T echnology ( N…Legal and ethical issues in safe blood transfusion (2014)Legal and ethical issues in s…The Risk of Transfusion-Transmitted Viral Infections (1996)Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population (2002)Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing (2004)Hepatitis B, hepatitis C and HIV transfusion‐transmitted infections in the 21st century (2010)Transfusion‐associated infections: 50 years of relentless challenges and remarkable progress (2010)Donor Testing and Risk: Current Prevalence, Incidence, and Residual Risk of Transfusion-Transmissible Agents in US Allogeneic Donations (2011)Results of Viral Marker Screening of Unpaid Blood Donations and Probability of Window Period Donations in 1997 (2000)Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus (2008)Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6‐year survey (2008)Screening Donated Blood for Transfusion Transmitted Infections by Serology along with NAT and Response Rate to Notification of Reactive Results: An Indian Experience (2014)Nucleic acid amplification testing in Indian blood banks: A review with perspectives (2017)History and Future of Nucleic Acid Amplification Technology Blood Donor Testing (2019)High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan (2003)Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States (2004)International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009 (2011)Individual donor-nucleic acid testing for human immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and its role in blood safety (2015)Seroprevalence & changing trends of transfusion-transmitted infections amongst blood donors in a Regional Blood Transfusion Centre in north India (2017)Recommendations for Reporting Cost-effectiveness Analyses (1996)Probability of Viremia with HBV, HCV, HIV, and HTLV among Tissue Donors in the United States (2004)Estimating the cost of blood: past, present, and future directions (2007)Moving on from voluntary non‐remunerated donors: who is the best blood donor? (2011)Hemovigilance Program-India (2013)Individual donor nucleic acid testing for blood safety against HIV-1 and hepatitis B and C viruses in a tertiary care hospital. (2013)Current status of blood banks in India (2016)Revolutionizing blood bank inventory management using the TOC thinking process: An Indian case study (2017)A review of legal, regulatory, and policy aspects of blood transfusion services in India (2021)The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection (1997)Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting (1999)Window‐period human immunodeficiency virus transmission to two recipients by an adolescent blood donor (2004)One‐year experience of nucleic acid technology testing for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations (2009)Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource‐poor settings (2005)Impact of individual‐donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa (2009)Trends in prevalence, incidence, and residual risk of major transfusion‐transmissible viral infections in United Arab Emirates blood donors: impact of individual‐donation nucleic acid testing, 2004 through 2009 (2012)Three-Year Experience in NAT Screening of Blood Donors for Transfusion Transmitted Viruses in Croatia (2017)Markers for Transfusion- Transmissible Infections in North Indian Voluntary and Replacement Blood Donors: Prevalence and Trends 1989-1996 (1997)Comparison of seropositivity of HIV, HBV, HCV and syphilis in replacement and voluntary blood donors in western India. (2001)Prevalence of HIV and VDRL seropositivity in blood donors of Delhi. (2005)Family/friend donors are not true voluntary donors (2012)Trends in Transfusion Transmitted Infections Among Replacement Blood Donors in Karachi, Pakistan (2013)Transfusion transmissible infections among blood donors from a sub-Himalayan rural tertiary care centre in Darjeeling, India (2015)A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors (2005)Nucleic acid testing for blood banks: An experience from a tertiary care centre in New Delhi, India (2013)Assessing the global burden of hemorrhage: The global blood supply, deficits, and potential solutions (2021)Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing (2005)Assessing the impact of HBV NAT on window period reduction and residual risk (2006)
this work references cited by second hop

References

  • 2010Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing287 cited
  • 2003The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donations264 cited
  • 2002Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window‐phase donations not detected by NAT117 cited
  • 2002Yield of HCV and HIV‐1 NAT after screening of 3.6 million blood donations in central Europe91 cited
  • 2008Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus -1 & hepatitis B & C viruses in Indian blood donors.73 cited
  • 2009Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions73 cited
  • 2010Patterns of infections among blood donors in a tertiary care centre: a retrospective study.51 cited
  • 2012Need for Nucleic Acid Testing in Countries with High Prevalence of Transfusion-Transmitted Infections48 cited
  • 2010Nucleic acid testing (NAT) in high prevalence–low resource settings47 cited

Cited by

  • 2014Legal and ethical issues in safe blood transfusion22 cited
  • 2014Nucleic A cid T echnology ( NAT ) testing for blood screening: impact of individual donation and M ini P ool – NAT testing on analytical sensitivity, screening sensitivity and clinical sensitivity16 cited
  • 2017A study of centralized individual donor nucleic acid testing for transfusion transmitted infections to improve blood safety in Karnataka, India

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

11 cited
  • 2019Seven Years Experience in NAT Testing of Blood Donors in a Tertiary Care Centre7 cited
  • 2022Blood Donation Screening of Transfusion-Transmissible Viral Infection Using Two Different Nucleic Acid Testing (NAT) Platforms: A Single Tertiary Care Oncology Centre Experience6 cited